By M&A — Advising Nasdaq-listed Neuphoria Therapeutics Inc. on its USD250M merger with AIM-listed Scancell Holdings Winston Taylor
Auto-published by the finit.news Events monitor from M&A; summarized by AI and may contain errors — verify against the primary source. July 29, 2026.